Dr. Jonathan L. Berkowitz, M.D., PH.D.
Medical Oncology (Medical Oncology Physician)
2401 W University Ave
Muncie, IN 47303
Who else practices at this address →
Delaware County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- State University of New York at Buffalo School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 362
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: State University of New York at Buffalo School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
IN license 01081263A -
Hematology (Internal Medicine) Physician
IN license 01081263A -
Hematology & Oncology Physician
CA license A116529
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Indiana University Health Indianapolis, IN
- Indiana University Health Ball Memorial Hospital Muncie, IN
- Reid Health Richmond, IN
- Henry County Memorial Hospital New Castle, IN
- Indiana University Health Jay, Inc. Portland, IN
Medical groups
- Iu Health Medical Group LLC (4,462 clinicians)
- Indiana University Health Ball Memorial Physicians Inc (232 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 362
- Services billed
- 1,350
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 891 | 258 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 166 | 100 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 101 | 35 |
| Established patient office or other outpatient visit, 30-39 minutes | 79 | 65 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 63 | 25 |
| Injection of drug or substance under skin or into muscle | 63 | 25 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 29 | 20 |
| Advance care planning, first 30 minutes | 26 | 22 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Muncie, IN | 211 |
| Prednisone Other prescribers in Muncie, IN | 209 |
| Tramadol Hcl Other prescribers in Muncie, IN | 157 |
| Olanzapine Other prescribers in Muncie, IN | 143 |
| Trazodone Hcl Other prescribers in Muncie, IN | 140 |
| Eliquis (apixaban) Other prescribers in Muncie, IN | 127 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Muncie, IN | 107 |
| Furosemide Other prescribers in Muncie, IN | 96 |
| Letrozole Other prescribers in Muncie, IN | 89 |
| Alendronate Sodium Other prescribers in Muncie, IN | 86 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $48.79 in total to this clinician.
| Acrotech Biopharma Inc. | $25.08 |
|---|---|
| Novartis Pharmaceuticals Corporation | $23.71 |
| Education | $25.08 |
|---|---|
| Food and Beverage | $23.71 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Acrotech Biopharma Inc. Jan 15, 2025 | Education BELEODAQ · ONCOLOGY · in-kind | $25.08 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $50,721 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib …
Merck Sharp & Dohme LLC - A phase iii, randomized, open-label, multicenter study evaluating the efficacy and safety of divaras
Genentech, Inc. - Phase 2 Multicenter Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd DS-8201a) for the Treatment of Selected HER2 Expressing Tumours (DESTINY-PanTumor02)
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.